INTRODUCTION
• Psoriasis affects ~3% of adults in the US and ~2-6% in Europe, [1] [2] [3] and most patients develop the disease in the third decade of life 4
• The correlation between psoriasis and reduced quality of life has been well-documented, [5] [6] [7] with more severe forms of the disease associated with greater reduction in quality of life 5
• Psoriasis is negatively correlated with work productivity, and patients with more severe disease experience increased productivity loss [8] [9] [10] • Certolizumab pegol (CZP) is the only PEGylated, Fc-free, anti-tumor necrosis factor (TNF) biologic currently under development for the treatment of moderate-to-severe chronic plaque psoriasis and has demonstrated efficacy and safety in previous psoriasis trials 11, 12 • CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) are ongoing phase 3 trials designed to assess the efficacy and safety of CZP compared with placebo; patient-reported quality of life and work productivity from the first 48 weeks of these studies are presented here
METHODS

Study Design
• CIMPASI-1 and CIMPASI-2 are replicate, phase 3, randomized, double-blind, placebo-controlled, multicenter studies conducted in North America and Europe • Patients were randomized 2:2:1 to CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (following 400 mg loading dose at Weeks 0, 2, and 4), or placebo Q2W for 16 weeks (Figure 1) • At Week 16, patients continued to receive treatment through Week 48 according to the following criteria:
-CZP 400 mg Q2W-and CZP 200 mg Q2W-treated psoriasis area and severity index (PASI) 50 responders (≥50% reduction in PASI) continued to receive their initial 
RESULTS
Patient Disposition, Demographics, and Baseline Characteristics
• In CIMPASI-1|CIMPASI-2, 88|87 patients were randomized to CZP 400 mg Q2W, 95|91 to CZP 200 mg Q2W, and 51|49 to placebo (Figure 2) • In both studies, at least 90% of patients in each treatment arm completed Week 16 ( • Baseline DLQI scores were comparable across treatment groups for both studies while WPAI score trends varied slightly by study ( (Figure 3) • Improvement was maintained with both CZP 400 mg Q2W and 200 mg Q2W at Week 48 (Figure 3) 
Figure 3. DLQI Mean Scores at Baseline, Week 16, and
Week 48 Figure 4) • Improvement was maintained for CZP 400 mg Q2W and 200 mg Q2W at Week 48 (Figure 4) 
Figure 4. DLQI Minimal Clinically Important Difference a Responder Rates Through Week 48
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